ReviewCNS drug reviews2007
The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268.
Review in CNS drug reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.Drug safety · 2010Pooled it
- Task-Specific Effects of mGlu2/3 Receptor Agonist LY379268 on MK-801-Induced Behavioral and Neural Dysfunctions in Rats.Physiological research · 2026Article
- Glutamate transmission in the prelimbic cortex and nucleus accumbens shell is involved in ethanol reinforcement and drinking in rats.Frontiers in behavioral neuroscience · 2026Article
- Triggered temptations: A new procedure to compare reward-seeking behaviour induced by discriminative and conditioned stimuli in rats.Psychopharmacology · 2025Article
- Activating group II metabotropic glutamate receptors in the basolateral amygdala inhibits increases in reward seeking triggered by discriminative stimuli in rats.The international journal of neuropsychopharmacology · 2025Article
- Glutamate as a Therapeutic Substrate in Migraine.International journal of molecular sciences · 2025Review
- Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.Translational psychiatry · 2025Review
- Structural basis of orientated asymmetry in a mGlu heterodimer.Nature communications · 2024Article
- Metabotropic glutamate group II receptor activation in the ventrolateral dorsal striatum suppresses incentive motivation for cocaine in rats.Psychopharmacology · 2023Article
- Effects of the mGlu2/3 receptor agonist LY379268 on two models of disturbed auditory evoked brain oscillations in mice.Translational psychiatry · 2023Article
- Metabotropic group II glutamate receptors mediate cue-triggered increases in reward-seeking behaviour.Psychopharmacology · 2023Article
- Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome.Neuropharmacology · 2022Article
- Metabotropic group II glutamate receptors in the basolateral amygdala mediate cue-triggered increases in incentive motivation.Psychopharmacology · 2021Article
- G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.Molecular neurobiology · 2021Review
- Control of impulsivity by GCommunications biology · 2021Article
- Metabotropic glutamate 2,3 receptor stimulation desensitizes agonist activation of G-protein signaling and alters transcription regulators in mesocorticolimbic brain regions.Synapse (New York, N.Y.) · 2021Article
- Article
- Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update.Current neuropharmacology · 2020Review
- Amygdala group II mGluRs mediate the inhibitory effects of systemic group II mGluR activation on behavior and spinal neurons in a rat model of arthritis pain.Neuropharmacology · 2019Article
- LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in AβPP/PS1 Mice.Journal of Alzheimer's disease : JAD · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of group II metabotropic glutamate (mGlu2/3) receptors reduces excessive glutamate release that is often associated with neurodegenerative and psychiatric disorders. This finding encouraged the search for potent and selective agonists as potential therapeutic agents. The search led to the discovery of LY379268 {(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic acid}, which is a highly potent and systemically available mGlu2/3 receptor agonist. LY379268 was effective in several animal models of stroke, epilepsy, drug abuse, schizophrenia, and pain. Suppression of motor activity is the major side effect of LY379268. Upon repeated administration tolerance develops to this side effect, while the therapeutic effects of LY379268 remain. To date, no clinical data with LY379268 are available. This review article summarizes the preclinical pharmacology of LY379268.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.